HistrelinLong-acting GnRH agonist implant
Histrelin provides sustained GnRH-agonist exposure through an implant. In central precocious puberty, the aim is to suppress an inappropriately early activation of the reproductive hormone system.
What is Histrelin?
Histrelin is a GnRH agonist available in an implant formulation used for central precocious puberty. Treatment aims to suppress an inappropriately early activation of the puberty hormone pathway. 1 2
How it works
Sustained stimulation of pituitary GnRH receptors leads to downregulation, reducing gonadotropin signalling and downstream sex-hormone production. An initial stimulatory phase can occur. 2
Effects studied
What does the evidence show?
Central-precocious-puberty studies and product-label lead
A prolonged signal changes the response
Histrelin stimulates GnRH receptors, but continuous exposure eventually suppresses pituitary release of LH and FSH. This lowers downstream sex hormones. The implant prolongs delivery. The diagnosis and intended treatment outcome still need to be defined.
What central precocious puberty means
In this condition, the brain’s puberty signalling starts earlier than expected. Specialist assessment considers the progression of physical changes, growth and bone maturation, rather than relying on a single symptom. Suppressing the signal can slow that process while treatment is needed.
What the studies assess
The retained paediatric research measures hormonal suppression and related clinical changes. These results do not automatically answer every question about eventual adult height, long-term wellbeing or the ideal duration for an individual child. Those outcomes need continued assessment in their own right. 1 2
Implant insertion, removal and monitoring
Insertion and removal are procedures, and local reactions or difficulties removing an implant can matter. Initial hormone stimulation and subsequent suppression have different effects. Historical histrelin products for prostate cancer should remain distinct from the paediatric product; the same ingredient does not make the populations or treatment plans interchangeable.
Safety & status
Implant placement and removal require attention, including local reactions and procedural issues. Hormonal changes and the early stimulatory phase need clinical monitoring. 2
Country and product status
Product indications and availability vary by country; current EU and Swiss status has not been independently checked for this draft.
Frequently asked questions
Is it a medicine for ordinary variations in puberty timing?
The described indication is central precocious puberty, a defined diagnosis requiring assessment. 2
Does controlling hormone levels prove an adult-height benefit?
No. Hormone suppression, bone-age change and final height need to be assessed as separate outcomes. 1
Further reading
Sources
This entry was rewritten from our research archive. References below are reading leads unless a completed check is explicitly noted; a full independent evidence and regulatory review is still pending.
- Retained paper reference Archive research lead · Retained archive reference; not independently checked for this draft
- Retained source reference Archive research lead · Retained archive reference; not independently checked for this draft
Research provenance
This name was discovered in the Superpower peptide index, archived 26 October 2026. Its ratings and reviewer attribution have not been adopted as our own. The archive informed this original editorial draft; independent source review is still pending.